The most important intervention to lower stroke recurrence rates is to ensure that every eligible patient adheres to antihypertensive therapy guidelines. Although there is no strong evidence that acute in-hospital antihypertensive treatment is either beneficial or harmful, there is robust evidence that long-term adherence is promoted by antihypertensive prescription in-hospital or at discharge.
Hypertension is the most important modifiable risk factor for ischemic stroke and intracerebral hemorrhage (ICH). 1 Antihypertensives substantially lower recurrence risk of multiple stroke subtypes, whether ischemic or hemorrhagic ''small vessel disease'' (arteriolosclerosis or cerebral amyloid angiopathy), large artery atherosclerosis, or cardioembolism. [2] [3] [4] In addition, antihypertensive treatment reduces myocardial infarction risk 3 and may reduce risk of renal disease progression and symptomatic heart failure. No group is clearly harmed by antihypertensive therapy, except potentially hypoperfusion-related ischemic stroke from large vessel stenosis.
Patient and medical professional adherence to secondary prevention guidelines is suboptimal initially and declines over time. Adherence to antihypertensive therapy is the most important facet of secondary prevention. To prevent stroke recurrence, we must follow evidence-based strategies proven to improve adherence.
There are potential barriers to commencing antihypertensive therapy post-discharge. Patients may not attend stroke specialist follow-up, and many centers lack resources to follow up every admitted stroke patient. General practitioners may diverge from discharge recommendations, especially if the patient is ''normotensive,'' and therefore not commence treatment. Patients may be less motivated to adhere to treatment if commenced post-acutely.
Are these fears borne out in clinical practice? Yes-compelling data from various health systems in multiple countries show that medication started in an acute hospital setting or at discharge makes long-term adherence more likely than relying on post-acute follow-up.
The population-based EXPRESS trial of TIA/minor stroke treatment found that adherence to recommended therapy was dramatically improved if commenced at acute neurologist contact, versus faxing instructions to general practitioners. 5 Antihypertensives were commenced acutely in this trial unless blood pressure was lower than 130 systolic on repeated measures, with no signal of harm.
The population benefit of this approach was also supported by the long-term follow-up in the North East Melbourne Stroke Incidence study. Although this population is relatively affluent in world terms, with reasonable access to post-stroke outpatient care by stroke experts, researchers demonstrated that prescription of medication at hospital discharge was the strongest single predictor of ongoing medication use at 10 year post-stroke. 6 Touze et al. 7 from France showed in-hospital (as opposed to outpatient) initiation or reinforcement of appropriate antihypertensives during hospitalization was the main factor associated with longer term appropriate blood pressure control. Similarly, Tsai et al. 8 in Canada found patients provided with a hospital script at discharge had better adherence at seven days, one and two years post-stroke.
Balanced against these benefits are only potential harms. In ischemic stroke, while there are reasonable theoretical concerns that blood pressure lowering hyperacutely may worsen penumbral cerebral hypoperfusion, there is no evidence that inpatient initiation of treatment is overall harmful 9 (although one might reasonably delay commencement when an arterial occlusion or high-grade stenosis is demonstrated). Conversely, moderately aggressive acute blood pressure lowering to long-term target in ICH patients is possibly beneficial. 10 While inpatients may potentially develop other treatment side-effects (such as cough, gout, electrolyte disturbance, postural hypotension, and renal dysfunction), perhaps it is safer to monitor these potential complications in an inpatient rather than outpatient setting.
Agreed, the event curves in the PROGRESS antihypertensive trial only diverged after several months, and an active ''run-in'' period was a pre-requisite to randomization. 3 In an ideal world, if we reviewed every patient one month post-discharge and then reliably commenced antihypertensive treatment, would long-term adherence and clinical endpoint rates be any worse? Probably not. But we do not live in an ideal world. Stroke prevention medications only work if patients take them, and given ''real-world'' data strongly suggest that antihypertensive medication adherence is better when prescribed in-hospital or at discharge, the burden of ''real-world'' proof lies at the feet of those who propose the superiority of an alternate approach.
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